EP2489361
Notkun frumugagndræpra peptíðlata JNK boðmiðlunartaugabrautar við að meðhöndla ýmsa sjúkdóma
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
2.6.2009EP published:
16.4.2014EP application number:
12000663.0
EP translation filed:
28.5.2014Grant published:
15.6.2014EPO information:
European Patent Register
Max expiry date:
1.6.2029Expiry date:
1.6.2019
Title:
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
Timeline
Today
2.6.2009EP application
16.4.2014EP Publication
28.5.2014Translation submitted
15.6.2014Registration published
1.6.2019Expires
Owner
Name:
Xigen Inflammation Ltd.Address:
Arch. Makariou III 195 Neocleous House, 3030, Limassol, CY
Inventor
Name:
Bonny, ChristopheAddress:
Lausanne, CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
PCT/EP2008/004341Date:
30.5.2008Country:
WO
Classification
Categories:
A61K 38/01, A61K 38/03, A61K 38/04, A61P 9/00, A61P 11/00, A61P 17/00, A61P 25/00, A61P 31/12, A61P 37/00
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 18.6.2014
Expires: 1.6.2015
Payer: Guðjón Styrkársson, hrl.
Number: 7
Paid: 22.6.2015
Expires: 1.6.2016
Payer: Guðjón Styrkársson, hrl.
Number: 8
Paid: 20.6.2016
Expires: 1.6.2017
Payer: Guðjón Styrkársson, hrl.
Number: 9
Paid: 20.7.2017
Expires: 1.6.2018
Payer: Guðjón Styrkársson, hrl.
Number: 10
Paid: 18.10.2018
Expires: 1.6.2019
Payer: Guðjón Styrkársson, hrl.